BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14362 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Rolf Ljung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences Lund-Pediatrics, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
To report the long‐term safety and efficacy of BAY 81‐8973 in the LEOPOLD Kids extension phase.
Methods
Patients received BAY 81‐8973 (25–50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase ( n = 82). Efficacy endpoints were assessed in patients without high‐titre inhibitors/immune tolerance induction ( n = 67).
Results
Children ( n = 82) received BAY 81‐8973 for a median of 3.1 years per patient and a median of 405 exposure days per patient. Long‐term BAY 81‐8973 treatment was well tolerated, with no cases of de novo inhibitor development in the extension phase. Annualised bleeding rates (ABRs) within 48 h of prophylaxis were low for all bleeds (median [IQR], 0.7 [0–1.9]; mean, 1.4 [SD, 2.1]) and for joint bleeds (median [IQR], 0 [0–0.7]; mean, 0.5 [SD, 1.1]) ( n = 67). Twenty‐one of 67 patients (31.3%) had zero bleeds within 48 h of prophylaxis; the treatment response was ‘good’/‘excellent’ in 87.9% of bleeds, and most bleeds resolved with ≤ 2 BAY 81‐8973 infusions (83.5%).
Conclusion
Long‐term BAY 81‐8973 treatment is well tolerated and maintains low ABRs for all bleeds and joint bleeds in children with severe haemophilia A. Trial Registration: ClinicalTrials.gov identifier: NCT01311648
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences Lund-Pediatrics, Lund University, Lund, Sweden.
- McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada.
- Department of Pediatric Hematology & Oncology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
- Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Milan, Italy.
- Humanitas University, Milan, Italy.
- Global Medical Affairs, Bayer, Mexico City, Mexico.
ORCID-Profile: Rolf Ljung
Förderung
- Bayer
Zitieren
APA
Ljung, R., Chan, A. K. C., Ahuja, S. P., Mancuso, M. E., Marquez, J. F. C., Volk, F., Blanchette, V., Kerlin, B. A., Trakymiene, S. S., Glosli, H., & Kenet, G. (2025). BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study. European Journal of Haematology. https://doi.org/10.1111/ejh.14362
Vancouver
Ljung R, Chan AKC, Ahuja SP, Mancuso ME, Marquez JFC, Volk F, et al. BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study. European Journal of Haematology. 2025. doi:10.1111/ejh.14362
BibTeX
@article{Ljung2025,
author = {Ljung, Rolf and Chan, Anthony K C and Ahuja, Sanjay P and Mancuso, Maria Elisa and Marquez, Jose Francisco Cabre and Volk, Florian and Blanchette, Victor and Kerlin, Bryce A and Trakymiene, Sonata Saulyte and Glosli, Heidi and Kenet, Gili},
title = {BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14362}
}
EUVIMED